Vaccine formulations in development for non-Hodgkin lymphomas.
Vaccine formulation . | Starting material . | Production time . | Target tumor antigen(s) . | Phase of clinical development . | Potential applicability . | References . |
---|---|---|---|---|---|---|
Idiotype-based | FNA or core biopsy | Tumor-specific Well-defined | B-cell malignancies | |||
Id protein-KLH | > 2 mo | Phase 3 | 10,15–17,23,30 | |||
Id protein-DC | > 2 mo | Phase 2 | 22 | |||
DNA | < 1 mo | Phase 1 | 37,38,50 | |||
Membrane proteoliposome | Excisional biopsy | < 1 mo | Multiple Undefined | Phase 1 | Multiple malignancies | 39,40 |
Tumor-cell based | Excisional biopsy | Multiple Undefined | Multiple malignancies | |||
GM-CSF transduced | < 1 mo | Phase 2 | 41 | |||
CD40 activated | < 1 mo | Phase 1 | 42 | |||
HSP-96 | < 1 mo | Phase 1 | 45 |
Vaccine formulation . | Starting material . | Production time . | Target tumor antigen(s) . | Phase of clinical development . | Potential applicability . | References . |
---|---|---|---|---|---|---|
Idiotype-based | FNA or core biopsy | Tumor-specific Well-defined | B-cell malignancies | |||
Id protein-KLH | > 2 mo | Phase 3 | 10,15–17,23,30 | |||
Id protein-DC | > 2 mo | Phase 2 | 22 | |||
DNA | < 1 mo | Phase 1 | 37,38,50 | |||
Membrane proteoliposome | Excisional biopsy | < 1 mo | Multiple Undefined | Phase 1 | Multiple malignancies | 39,40 |
Tumor-cell based | Excisional biopsy | Multiple Undefined | Multiple malignancies | |||
GM-CSF transduced | < 1 mo | Phase 2 | 41 | |||
CD40 activated | < 1 mo | Phase 1 | 42 | |||
HSP-96 | < 1 mo | Phase 1 | 45 |